Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697072 · ClinicalTrials.gov registry record · Phase 3
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT01697072 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 609 participants.
The verdict
NCT01697072, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- OTHER Placebo
- DRUG Epirubicin
- DRUG Rilotumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01697072
The ClinicalTrials.gov registry entry for NCT01697072 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT01697072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01697072 about?
NCT01697072 is a clinical study titled "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma". This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
What is the current status of trial NCT01697072?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2012-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01697072?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Placebo (OTHER), Epirubicin (DRUG), Rilotumumab (DRUG).
Who is sponsoring clinical trial NCT01697072?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.